NCT00086671View on ClinicalTrials.gov

Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

PHASE2CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Multiple Sclerosis
Interventions
DRUG

ABT-874/Human monoclonal antibody against IL-12

DRUG

Placebo

Trial Locations (44)

12205

Site Reference ID/Investigator# 110, Albany

18103

Site Reference ID/Investigator# 114, Allentown

28207

Site Reference ID/Investigator# 117, Charlotte

30309

Site Reference ID/Investigator# 108, Atlanta

30327

Site Reference ID/Investigator# 109, Atlanta

32308

Site Reference ID/Investigator# 151, Tallahassee

33136

Site Reference ID/Investigator# 111, Miami

40503

Site Reference ID/Investigator# 261, Lexington

43210

Site Reference ID/Investigator# 113, Columbus

45409

Site Reference ID/Investigator# 157, Dayton

46260

Site Reference ID/Investigator# 152, Indianapolis

48201

Site Reference ID/Investigator# 116, Detroit

49684

Site Reference ID/Investigator# 158, Traverse City

60062

Site Reference ID/Investigator# 105, Northbrook

60528

Site Reference ID/Investigator# 149, Frankfurt

63110

Site Reference ID/Investigator# 124, St Louis

66214

Site Reference ID/Investigator# 258, Lenexa

72205

Site Reference ID/Investigator# 156, Little Rock

77030

Site Reference ID/Investigator# 128, Houston

80304

Site Reference ID/Investigator# 119, Boulder

85013

Site Reference ID/Investigator# 107, Phoenix

85351

Site Reference ID/Investigator# 163, Sun City

89052

Site Reference ID/Investigator# 259, Henderson

92618

Site Reference ID/Investigator# 154, Irvine

92653

Site Reference ID/Investigator# 161, Laguna Hills

95817

Site Reference ID/Investigator# 84, Sacramento

03766

Site Reference ID/Investigator# 153, Lebanon

05201

Site Reference ID/Investigator# 155, Bennington

J4V 2H1

Site Reference ID/Investigator# 132, Greenfield Park

B3H 3A7

Site Reference ID/Investigator# 130, Halifax

K1H 8L6

Site Reference ID/Investigator# 82, Ottawa

J1H 5N4

Site Reference ID/Investigator# 169, Sherbrooke

V6T 2B5

Site Reference ID/Investigator# 134, Vancouver

4818 CK

Site Reference ID/Investigator# 137, Breda

3435 CM

Site Reference ID/Investigator# 148, Nieuwegein

6533 PA

Site Reference ID/Investigator# 138, Nijmwegen

6131 BK

Site Reference ID/Investigator# 139, Sittard

L97LJ

Site Reference ID/Investigator# 159, Liverpool

SE1 1UL

Site Reference ID/Investigator# 140, London

NE1 4LP

Site Reference ID/Investigator# 142, Newcastle upon Tyne

NG7 2UH

Site Reference ID/Investigator# 141, Nottingham

OX2 6HE

Site Reference ID/Investigator# 144, Oxford

ST4 7LN

Site Reference ID/Investigator# 143, Stoke-on-Trent

E1 1 BB

Site Reference ID/Investigator# 160, Whitechapel

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT00086671 - Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter